Quest Partners LLC Buys New Shares in AngioDynamics, Inc. (NASDAQ:ANGO)

Quest Partners LLC purchased a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 36,649 shares of the medical instruments supplier’s stock, valued at approximately $285,000. Quest Partners LLC owned approximately 0.09% of AngioDynamics at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ANGO. Systematic Financial Management LP boosted its position in AngioDynamics by 8.4% during the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock valued at $12,763,000 after purchasing an additional 162,972 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of AngioDynamics by 41.9% in the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after buying an additional 529,861 shares during the last quarter. Royce & Associates LP increased its holdings in AngioDynamics by 10.8% during the third quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier’s stock worth $7,672,000 after buying an additional 96,138 shares during the last quarter. Western Standard LLC lifted its stake in AngioDynamics by 878.5% in the first quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock valued at $3,072,000 after acquiring an additional 469,906 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in AngioDynamics by 7.2% in the third quarter. Assenagon Asset Management S.A. now owns 425,108 shares of the medical instruments supplier’s stock valued at $3,307,000 after acquiring an additional 28,499 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of AngioDynamics stock in a transaction dated Monday, October 7th. The stock was bought at an average price of $6.03 per share, with a total value of $120,600.00. Following the completion of the transaction, the chief executive officer now owns 681,582 shares in the company, valued at $4,109,939.46. The trade was a 3.02 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have bought a total of 22,568 shares of company stock valued at $135,847 in the last ninety days. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $6.99 on Tuesday. The stock has a market cap of $284.03 million, a PE ratio of -1.12 and a beta of 0.67. The firm has a 50-day moving average of $6.94 and a 200-day moving average of $6.80. AngioDynamics, Inc. has a 52-week low of $5.26 and a 52-week high of $8.25.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. During the same period last year, the business posted ($0.12) earnings per share. The business’s revenue for the quarter was down 14.2% compared to the same quarter last year. As a group, analysts predict that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ANGO. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a research note on Friday, October 4th. Canaccord Genuity Group lowered their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, October 4th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.